<DOC>
	<DOCNO>NCT00710801</DOCNO>
	<brief_summary>The purpose study learn different immunosuppressant therapy impact recurrent hepatitis C virus infection new liver liver transplant . We evaluate Cyclosporin A superior effect recurrent Hepatitis C virus ( HCV ) infection Tacrolimus .</brief_summary>
	<brief_title>Assessment Biomarkers Recurrent HCV Infection Post-liver Transplantation</brief_title>
	<detailed_description>We address hypothesis CSA superior antiviral effect HCV Tacrolimus assess serial HCV RNA level serum . We plan address hypothesis CSA efficient limit viremia Tacrolimus viremia predictive long-term clinical outcome hepatic fibrosis know impact graft patient survival</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>About undergo primary liver transplant ( include live donor , split liver ) HCV positive . Willing capable give write consent study participation Expected capable study participation full 24 month posttransplantation . Allograft biopsies possible Expected use calcineurin inhibitor ( Neoral Tacrolimus ) primary immunosuppression An immunosuppressive regimen consist calcineurin inhibitor ( Neoral Tacrolimus ) combination Simulect MYCOPHENOLATE SODIUM This multiorgan transplant patient previously transplant organ . This liver transplant nonheart beat donor . This ABO incompatible transplant . Patients serum creatinine level &gt; 250 umol/L . The recipient seropositive human immunodeficiency virus ( HIV ) antibody . Fulminant liver failure reason transplant . Patient participate clinical trial involve exploratory drug There know malignancy , history malignancy , successfully treat nonmetastatic basal squamous cell carcinoma skin , hepatocellular carcinoma le 5 cm meeting Milan criterion transplantation5 . The patient transplant hepatic malignancy great 5 known lesion . Severe coexist disease present unstable medical condition present could affect study objective . A female transplant candidate pregnant , lactate childbearing potential practicing acceptable method contraception . An unlicensed drug therapy administer within one month prior study entry therapy institute posttransplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>HCV</keyword>
	<keyword>Liver Transplant</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Myfortic</keyword>
</DOC>